NCT06078306 2024-04-22
CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
Clinical Trials
11 trialsNCT05823701 2023-04-21
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05797948 2023-04-04
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT05772728 2023-03-16
Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT05182957 2023-01-31
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05559008 2022-11-09
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
Ruijin Hospital
Phase 1/2 Unknown
NCT04480125 2022-04-20
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy
Ruijin Hospital
Phase 2 Unknown
NCT05008666 2021-08-17
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
Sun Yat-sen University
Phase 2 Unknown
NCT04899414 2021-05-24
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
Peking University
Phase 2 Unknown
NCT04052659 2021-03-09
Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL
Peking University
Phase 2 Unknown
NCT03719989 2018-10-25
EPIC
Seoul National University Hospital
Phase 2 Unknown